Hangzhou Ronggu Biotechnology

Hangzhou Ronggu Biotechnology is a clinical-stage Chinese biotechnology company specializing in the development of innovative chimeric antigen receptor natural killer (CAR-NK) cell therapies and oncolytic virus immunotherapies for the treatment of solid tumors, hematological malignancies, and autoimmune diseases. Founded by leading clinical and scientific experts from Zhejiang University, Nanjing University, and Duke University, the company has established proprietary platforms including LEONCAR™ (Lentivirus Engineered Cord Blood NK Cell Therapy) and HTPNA-CAR (a high-throughput nanobody and biological function screening platform). Its pipeline features several advanced candidates, including RG-019 (targeting CD19) for B-cell non-Hodgkin lymphoma and systemic lupus erythematosus, and RG-CLDN18.2 (CB CAR-NK 182) for gastric and pancreatic cancers, which is currently in Phase 1 clinical trials. By overcoming traditional lentiviral transduction barriers in NK cells and achieving high-fold ex vivo expansion, Ronggu Biotechnology aims to deliver highly effective, off-the-shelf cellular immunotherapies.